Literature DB >> 26448659

In Vitro Stabilifighty Evaluation of Different Pharmaceutical Products Containing Meropenem.

Cristina Tomasello1, Anna Leggieri1, Roberta Cavalli2, Giovanni Di Perri3, Antonio D'Avolio4.   

Abstract

BACKGROUND: Meropenem is a beta-lactam antibiotic for treating multidrug-resistant gram-negative bacilli infections. The expiry of the drug's patent (Merrem) allowed the production of generics to be commercialized by a few companies, including Hospira and Hikma. The stability of these medicines after reconstitution as reported on a data sheet report is 6 hours for Merrem and 1 hour for generics.
OBJECTIVES: The aim of this work was to evaluate the stability profile of 3 products in 0.9% sodium chloride until 6 hours.
METHODS: Six polyolefin bags (2 for each drug, stored in the light and in the dark) were prepared for every test run (n =10) at concentrations of 4 and 10 mg/mL. All solutions were stored at controlled room temperature (25°C ± 3°C) and sampled immediately after preparation and at every hour until 6 hours had passed. The concentrations, pH changes, and the visual clarity were used as stability and compatibility indicators.
RESULTS: All 3 drugs retained over 95% of the initial concentration at 3 to 4 hours. At the sixth hour, all the concentrations decayed 8% to 10%. No statistical differences were observed in the percentage deviation values of the stability profile between generics and the branded drug.
CONCLUSION: The stability profile of the products in polyolefin bags, at 4 and 10 mg/mL, was superimposable during the period of analysis and seems to show small values of deviation (1%-2%). These data do not affect the pharmacokinetics because these variations could be attributed to the intra- and interindividual variability between patients. The products showed the same stability, and consequently they could be used interchangeably in hospital pharmacy.

Entities:  

Keywords:  UPLC-PDA; hospital pharmacy; meropenem; pharmacokinetic; stability

Year:  2015        PMID: 26448659      PMCID: PMC4589882          DOI: 10.1310/hpj5004-296

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  11 in total

1.  Stability and degradation kinetics of meropenem in powder for injection and reconstituted sample.

Authors:  Andreas S L Mendez; Jean Dalomo; Martin Steppe; Elfrides E S Schapoval
Journal:  J Pharm Biomed Anal       Date:  2006-03-14       Impact factor: 3.935

2.  Stability of meropenem in intravenous solutions.

Authors:  P R Patel; S E Cook
Journal:  Am J Health Syst Pharm       Date:  1997-02-15       Impact factor: 2.637

3.  Stability of meropenem and doripenem solutions for administration by continuous infusion.

Authors:  Karine Berthoin; Cécile S Le Duff; Jacqueline Marchand-Brynaert; Stéphane Carryn; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2010-02-21       Impact factor: 5.790

Review 4.  Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy.

Authors:  F Thalhammer; W H Hörl
Journal:  Clin Pharmacokinet       Date:  2000-10       Impact factor: 6.447

Review 5.  The pharmacology of meropenem, a new carbapenem antibiotic.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

6.  Stability of meropenem in normal saline solution after storage at room temperature.

Authors:  Sutep Jaruratanasirikul; Somchai Sriwiriyajan
Journal:  Southeast Asian J Trop Med Public Health       Date:  2003-09       Impact factor: 0.267

7.  Stability of a 1 beta-methylcarbapenem antibiotic, meropenem (SM-7338) in aqueous solution.

Authors:  Y Takeuchi; M Sunagawa; Y Isobe; Y Hamazume; T Noguchi
Journal:  Chem Pharm Bull (Tokyo)       Date:  1995-04       Impact factor: 1.645

8.  Thermal and alkaline stability of meropenem: degradation products and cytotoxicity.

Authors:  Andreas Mendez; Pedro Chagastelles; Eduardo Palma; Nance Nardi; Elfrides Schapoval
Journal:  Int J Pharm       Date:  2007-08-24       Impact factor: 5.875

Review 9.  Pharmacokinetic and pharmacodynamic properties of meropenem.

Authors:  David P Nicolau
Journal:  Clin Infect Dis       Date:  2008-09-15       Impact factor: 9.079

10.  Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients.

Authors:  C Robatel; L A Decosterd; J Biollaz; P Eckert; M D Schaller; T Buclin
Journal:  J Clin Pharmacol       Date:  2003-12       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.